Search Results

Filter
  • 1-10 of  6,975 results for ""Receptors, Vascular Endothelial Growth Factor""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.

  • Authors : Boyer DS; Retina-Vitreous Associates Medical Group, Beverly Hills, CA, USA.; Steinle NC

Subjects: Macular Edema*/Macular Edema*/Macular Edema*/drug therapy ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use

  • Source: Translational vision science & technology [Transl Vis Sci Technol] 2024 Dec 02; Vol. 13 (12), pp. 32.Publisher: Association for Research in Vision and Ophthalmology Country of Publication: United States NLM ID: 101595919 Publication Model: Print Cited

Record details

×
Academic Journal

Predictive Factors for Submacular Hemorrhage in Age-related Macular Degeneration: A Retrospective Study.

  • Authors : Moon H; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea.; Kang HG

Subjects: Tomography, Optical Coherence*/Tomography, Optical Coherence*/Tomography, Optical Coherence*/methods ; Intravitreal Injections* ; Retinal Hemorrhage*/Retinal Hemorrhage*/Retinal Hemorrhage*/diagnosis

  • Source: Korean journal of ophthalmology : KJO [Korean J Ophthalmol] 2024 Dec; Vol. 38 (6), pp. 471-479. Date of Electronic Publication: 2024 Oct 22.Publisher: KJO Country of Publication: Korea (South) NLM ID: 8804513 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2092-9382

Record details

×
Academic Journal

BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.

  • Authors : Płatkowska-Adamska B; Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland - .; Department of Ophthalmology, John Boni Fratres Lodziensis, Łódź, Poland - .

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/administration & dosage ; BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/adverse effects ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage

  • Source: Minerva medica [Minerva Med] 2024 Dec; Vol. 115 (6), pp. 643-650. Date of Electronic Publication: 2024 Oct 11.Publisher: Edizioni Minerva Medica Country of Publication: Italy NLM ID: 0400732 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population.

  • Authors : Fukuda Y; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.; Notomi S

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/administration & dosage ; Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Intravitreal Injections*

  • Source: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2024 Dec; Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Branch retinal vein occlusion treated with anti-VEGF: to switch or not to switch?

  • Authors : Shor R; Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Segal O

Subjects: Retinal Vein Occlusion*/Retinal Vein Occlusion*/Retinal Vein Occlusion*/drug therapy ; Retinal Vein Occlusion*/Retinal Vein Occlusion*/Retinal Vein Occlusion*/physiopathology ; Retinal Vein Occlusion*/Retinal Vein Occlusion*/Retinal Vein Occlusion*/diagnosis

  • Source: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie [Can J Ophthalmol] 2024 Dec; Vol. 59 (6), pp. e824-e829. Date of Electronic Publication: 2024 Feb 22.Publisher: Elsevier Country of Publication: England NLM ID: 0045312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1715-3360

Record details

×
Academic Journal

Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.

  • Authors : Wolf S; Department of Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of BioMedical Research, Bern, Switzerland.

Subjects: Macular Edema*/Macular Edema*/Macular Edema*/drug therapy ; Macular Edema*/Macular Edema*/Macular Edema*/diagnosis ; Macular Edema*/Macular Edema*/Macular Edema*/etiology

  • Source: Ophthalmology. Retina [Ophthalmol Retina] 2024 Dec; Vol. 8 (12), pp. 1163-1173. Date of Electronic Publication: 2024 Jun 26.Publisher: Published by Elsevier Inc. on behalf of American Academy of Ophthalmology Country of Publication: United States NLM ID: 101695048 Publication Model:

Record details

×
Academic Journal

VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept.

  • Authors : Sharma D; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Lau E

Subjects: Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/metabolism ; Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/genetics ; Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/metabolism

  • Source: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Nov 12; Vol. 121 (46), pp. e2322759121. Date of Electronic Publication: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway.

  • Authors : Lorenc P; Chair of Medical Biotechnology, Department of Cancer Immunology, Poznan University of Medical Sciences, 8 Rokietnicka St, Poznan 60-806, Poland; Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary St, Poznan 61‑866, Poland

Subjects: Neovascularization, Pathologic*/Neovascularization, Pathologic*/Neovascularization, Pathologic*/drug therapy ; Neovascularization, Pathologic*/Neovascularization, Pathologic*/Neovascularization, Pathologic*/metabolism ; Vascular Endothelial Growth Factor A*/Vascular Endothelial Growth Factor A*/Vascular Endothelial Growth Factor A*/metabolism

  • Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Nov; Vol. 180, pp. 117585. Date of Electronic Publication: 2024 Oct 22.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials.

  • Authors : Zarbin M; Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.; Tabano D

Subjects: Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage ; Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/therapeutic use

  • Source: Ophthalmology [Ophthalmology] 2024 Nov; Vol. 131 (11), pp. 1258-1270. Date of Electronic Publication: 2024 Jun 08.Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  6,975 results for ""Receptors, Vascular Endothelial Growth Factor""